The Translational Genomics Research Institute (TGen) today announced the selection of its Governing Board.

PHOENIX, Tuesday, Dec. 10 The Translational Genomics Research Institute (TGen) today announced the selection of its Governing Board.

The 22-member board, representing the academic, scientific, corporate and philanthropic communities locally and nationally, was elected by the seven members of the Interim Board.

TGen took an important step today with the establishment of its board, said Dr. Jeffrey Trent, President and Scientific Director. Our new board is reflective of both Arizona and the nation, and the unparalleled expertise of its members will serve us well.

Elected members of the Governing Board will serve two-year terms. TGen, an independent research institute, was established in July, the culmination of a statewide effort led by a task force appointed by Governor Jane Dee Hull.

We are fortunate to have members of the caliber elected today. They represent the very best in their fields and will lead TGen in its vital mission of improving human health, said Margie Emmermann, chair of the Interim Board.

The members elected today are: Jos A. Crdenas, Managing Partner of Lewis and Roca; Susan Clark-Johnson, Chairman and Chief Executive Officer, Phoenix Newspapers; Michael M. Crow, Ph.D., President of Arizona State University; Bennett Dorrance, Managing Director of DMB; Peter S. Fine, President and Chief Executive Officer, Banner Health System; Margaret Foti, Ph.D., Chief Executive Officer and Managing Editor, cancer research, American Association for Cancer Research; Bert A. Getz, Chairman and Director, Globe Corporation; Hon. Mark O. Hatfield, former U.S. Senator and former Governor of Oregon; John Haeger, Ph.D., President of Northern Arizona University; Hon. Christopher Herstam, President-elect, Arizona Board of Regents; Hon. Jane Dee Hull, Governor, State of Arizona; Hamilton Jordan, speaker and lecturer, former Chief of Staff for President Jimmy Carter and founder, Georgia Cancer Coalition; Peter W. Likins, Ph.D., President, University of Arizona; Hon. Ivan Makil, President, Salt River Pima-Maricopa Indian Community; John W. Murphy, Executive Director, The Flinn Foundation; Cindy K. Parseghian, Founder and Volunteer President, Ara Parseghian Medical Research Foundation; William J. Post, Chairman of the Board and Chief Executive Officer, Pinnacle West Capital Corporation; Franklyn G. Prendergast, M.D., Ph.D., Director, Mayo Clinic Cancer Center; Hon. Skip Rimsza, Mayor, City of Phoenix; Jeffrey M. Trent, Ph.D., President and Scientific Director, Translational Genomics Research Institute (TGen); Hon. William C. Turner, Chairman, Argyle Atlantic Corporation; Steven M. Weinberg, Commissioner, Arizona Disease Control Research Commission.

In its first action, the board elected Jos A. Crdenas, as chairman. Crdenas, managing partner of the law firm of Lewis and Roca and a specialist in commercial and civil litigation, brings a wealth of experience to the position. He is currently the President of the Arizona-Mexico Commission and was a member of the steering committee for the Arizona Partnership for the New Economy. He also served on the Arizona Hispanic Chamber of Commerce board and is currently a member of the boards of directors of Greater Phoenix Leadership, the East Valley Partnership and the Greater Phoenix Economic Council.

The board members look forward to guiding TGen as it explores important health issues. Our role is to assure its performance as a world-class research institute, Crdenas said.

In addition to welcoming new board members, Trent also lauded the work of the Interim Board, stating that TGen owes much of its progress to their extensive work.

The capability and diligence of the interim board members and their chair Margie Emmermann have been vital as we began our mission. I extend them the gratitude of our team, the people of Arizona and those who will be helped by TGen research in the future, said Trent.

The members of the Interim Board are: Barbara Barrett, Esq., President, Triple Creek Ranch; Linda J. Blessing, Ph.D., Executive Director, Arizona Board of Regents; Bennett Dorrance, Managing Director, DMB; Margie A. Emmermann, Director, Arizona Department of Commerce; Peter S. Fine, President and Chief Executive Officer, Banner Health System; John W. Murphy, Executive Director, The Flinn Foundation; Sheryl Sculley, Assistant City Manager, City of Phoenix.

TGen is an independent research institute with the mission of helping translate scientific discoveries into diagnostics, treatments and cures.


###

About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org


Search



Media Contact



RSS Feed

Newsletter